HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUNEONCO-B

10.450

-1.030-8.97%

Volume:4.74M

Turnover:50.85M

Market Cap:4.51B

PE:-11.45

High:11.560

Open:11.480

Low:10.300

Close:11.480

52wk High:16.800

52wk Low:4.310

Shares:432.00M

HK Float Shares:420.00M

Volume Ratio:0.71

T/O Rate:1.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.912

ROE:-53.53%

ROA:-25.66%

PB:7.75

PE(LYR):-11.45

PS:33.73

Loading ...

Overview Company News Filings

IMMUNEONCO-B (01541) Completes the Issuance of 24.2 Million Shares

ImmuneOnco Biopharmaceuticals (Shanghai) Completes Placing of New H Shares Under General Mandate

Hong Kong Stocks Movement | IMMUNEONCO-B (01541) Rises Over 5% as Treg Cell Therapy Gains Attention; Company Actively Advances Clinical Development of Tazlestobart

BUZZ-China's ImmuneOnco drops most in 6 months on discounted share sale

ImmuneOnco Biopharmaceuticals Seeking HK$351 Million via Stock Offering

MT Newswires Live

BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Placing Of Total 24.2 MLN New H Shares At HK$14.50 Per Share

ImmuneOnco Biopharmaceuticals Shanghai - Placing of Total 24.2 Mln New H Shares at HK$14.50 per Share

THOMSON REUTERS

Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 9% Again Following Phase III Clinical Trial Application Submission for IMM2510

Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 6% Again as Company Submits Phase III Clinical Trial Application for IMM2510 to CDE

Hong Kong Stock Announcements | YUNFENG FIN: Strategic Investment in Global Cryptocurrency Life Insurance Company Anthea and Strategic Cooperation

IMMUNEONCO-B (01541): Submits Phase III Clinical Trial Application for IMM2510

ImmuneOnco Biopharmaceuticals (Shanghai) Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China

IMMUNEONCO-B (01541): IMM0306 Phase III Clinical Trial Application for Treatment of Follicular Lymphoma

ImmuneOnco Biopharmaceuticals (Shanghai) Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China(Note: There is no indication of grant/funding or involvement of multiple organizations in the provided announcement; the news is about a regulatory application for a Phase III clinical trial.)

ImmuneOnco Biopharmaceuticals Shanghai Inc - Submits Phase Iii Trial Application for Imm0306

THOMSON REUTERS

Hong Kong Pharmaceuticals Rise as Trump Drug Tariffs Show Limited Impact; Q4 BD Events Expected

Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 12% as IMM2510's Two Phase III Registration Clinical Trials Submit EOP2

Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 10% on Positive Clinical Trial Progress, Maintains "Buy" Rating

ImmuneOnco Biopharmaceuticals' Loss Narrows in H1

MT Newswires Live

IMMUNEONCO-B (01541) Reports Interim Results with Revenue of RMB 38.027 Million, Surging 49,285.71% Year-over-Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/01541/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"IMMUNEONCO-B","latestPrice":10.45,"timestamp":1760688490002,"preClose":11.48,"halted":0,"volume":4738400,"delay":0,"floatShares":420000000,"shares":432000000,"eps":-0.9124620059264897,"marketStatus":"Closed","change":-1.03,"latestTime":"10-17 16:08:10","open":11.48,"high":11.56,"low":10.3,"amount":50854616,"amplitude":0.109756,"askPrice":10.46,"askSize":6800,"bidPrice":10.45,"bidSize":22800,"shortable":3,"etf":0,"ttmEps":-0.8375935911265768,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1760923800000},"marketStatusCode":5,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":11.48,"openAndCloseTimeList":[[1760664600000,1760673600000],[1760677200000,1760688000000]],"volumeRatio":0.706793,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":420000000,"roa":"-25.66%","roe":"-53.53%","lyrEps":-0.912462,"volumeRatio":0.706793,"shares":432000000,"dividePrice":0,"high":11.56,"amplitude":0.109756,"preClose":11.48,"low":10.3,"week52Low":4.31,"pbRate":"7.75","psRate":"33.73","week52High":16.8,"institutionHeld":0,"latestPrice":10.45,"committee":0.540541,"eps":-0.9124620059264897,"divideRate":0,"volume":4738400,"delay":0,"ttmEps":-0.8375935911265768,"open":11.48,"prevYearClose":5.16,"prevWeekClose":12.56,"prevMonthClose":13.42,"prevQuarterClose":13.42,"fiveDayClose":12.56,"twentyDayClose":11.52,"sixtyDayClose":10.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"Post Market","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-10-16","current":-12.357655,"percent":0.370937,"low":-30.003263,"twenty":-20.5304,"median":-13.129767,"eighty":-6.160271,"high":-2.993766,"avg":-13.747487,"sd":7.42777,"marketCap":4675892338},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555},{"date":"2025-05-16","current":-8.311097,"twenty":-24.799485,"median":-12.12195,"eighty":-5.751942,"marketCap":2843007711},{"date":"2025-05-23","current":-11.289802,"twenty":-24.776462,"median":-11.940532,"eighty":-5.771038,"marketCap":3873496179},{"date":"2025-05-30","current":-15.223569,"twenty":-24.763734,"median":-11.970101,"eighty":-5.797425,"marketCap":5246123111},{"date":"2025-06-06","current":-16.623143,"twenty":-24.617548,"median":-12.331836,"eighty":-5.827424,"marketCap":5743038499},{"date":"2025-06-13","current":-15.603079,"twenty":-24.258649,"median":-12.701975,"eighty":-5.862056,"marketCap":5392753881},{"date":"2025-06-20","current":-14.878015,"twenty":-24.00727,"median":-12.82804,"eighty":-5.90109,"marketCap":5132076957},{"date":"2025-06-27","current":-13.023121,"twenty":-23.933348,"median":-12.837907,"eighty":-5.91626,"marketCap":4504823106},{"date":"2025-07-04","current":-14.906416,"twenty":-23.89321,"median":-12.895238,"eighty":-5.935244,"marketCap":5156515418},{"date":"2025-07-11","current":-12.022018,"twenty":-23.818294,"median":-12.972072,"eighty":-5.957179,"marketCap":4154538489},{"date":"2025-07-18","current":-12.975089,"twenty":-23.597552,"median":-12.895238,"eighty":-5.971632,"marketCap":4480384645},{"date":"2025-07-25","current":-12.316929,"twenty":-23.410778,"median":-12.839078,"eighty":-5.984465,"marketCap":4268584643},{"date":"2025-08-01","current":-12.109688,"twenty":-23.260279,"median":-12.895238,"eighty":-5.992729,"marketCap":4170830796},{"date":"2025-08-08","current":-13.046774,"twenty":-23.142239,"median":-12.972072,"eighty":-6.013995,"marketCap":4504823106},{"date":"2025-08-15","current":-15.594562,"twenty":-23.052783,"median":-12.982136,"eighty":-6.023266,"marketCap":5376461574},{"date":"2025-08-22","current":-14.245172,"twenty":-22.717488,"median":-13.011166,"eighty":-6.052989,"marketCap":4895838493},{"date":"2025-08-29","current":-13.416028,"twenty":-22.485479,"median":-13.022379,"eighty":-6.061027,"marketCap":4439653875},{"date":"2025-09-05","current":-17.224047,"twenty":-22.314693,"median":-13.032106,"eighty":-6.075447,"marketCap":5694161576},{"date":"2025-09-12","current":-15.065483,"twenty":-22.014704,"median":-13.063177,"eighty":-6.087386,"marketCap":4989519263},{"date":"2025-09-19","current":-14.903882,"twenty":-21.818428,"median":-13.085834,"eighty":-6.113201,"marketCap":4932496186},{"date":"2025-09-26","current":-13.980202,"twenty":-21.168438,"median":-13.096763,"eighty":-6.121719,"marketCap":4614796184},{"date":"2025-10-03","current":-19.067762,"twenty":-21.059976,"median":-13.099741,"eighty":-6.122985,"marketCap":6309196195},{"date":"2025-10-10","current":-15.483575,"twenty":-20.658991,"median":-13.109708,"eighty":-6.128239,"marketCap":5115784649},{"date":"2025-10-16","current":-14.16321,"twenty":-20.5304,"median":-13.129767,"eighty":-6.160271,"marketCap":4675892338}],"updateTime":1760686842796},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1129055345","title":"IMMUNEONCO-B (01541) Completes the Issuance of 24.2 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1129055345","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129055345?lang=en_us&edition=fundamental","pubTime":"2025-10-16 12:20","pubTimestamp":1760588410,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that all conditions precedent to the placement agreement have been satisfied, and the delivery has been executed according to the terms and conditions of the placement...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2575431793","title":"ImmuneOnco Biopharmaceuticals (Shanghai) Completes Placing of New H Shares Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2575431793","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575431793?lang=en_us&edition=fundamental","pubTime":"2025-10-16 12:15","pubTimestamp":1760588159,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. has announced the completion of a placing of new H shares under a general mandate. All conditions precedent set out in the Placing Agreement have been fulfilled and the transaction has closed. The company will proceed with the relevant filing procedures in accordance with the rules of the China Securities Regulatory Commission. The placing is part of ImmuneOnco's efforts to strengthen its capital base and support ongoing business development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL1DQVwG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1111898434","title":"Hong Kong Stocks Movement | IMMUNEONCO-B (01541) Rises Over 5% as Treg Cell Therapy Gains Attention; Company Actively Advances Clinical Development of Tazlestobart","url":"https://stock-news.laohu8.com/highlight/detail?id=1111898434","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111898434?lang=en_us&edition=fundamental","pubTime":"2025-10-16 12:02","pubTimestamp":1760587336,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) has seen a surge of over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.47 million. According to recent updates from IMMUNEONCO-B, scientists Mary E. Blenko...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2574189958","title":"BUZZ-China's ImmuneOnco drops most in 6 months on discounted share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189958","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189958?lang=en_us&edition=fundamental","pubTime":"2025-10-09 12:04","pubTimestamp":1759982681,"startTime":"0","endTime":"0","summary":"BUZZ-China's ImmuneOnco drops most in 6 months on discounted share sale** Shares of ImmuneOnco Biopharmaceuticals Shanghai 1541.HK drop 13.5% to HK$14.41, on course for their biggest one-day pct decline since April 7** The China-based tumor immunotherapy developer plans sale of 24.2 mln new shares to third party investors in share placement, raising HK$350.9 mln  for R&D of therapy for treatment of solid tumors in China, among others ** The new shares will be issued at HK$14.50 apiece, or nearly 13% discount to Wednesday close of HK$16.66 each** YTD, stock up 180.8%, Hang Seng Biotech Index .HSBIO up 104.6%   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nL2N3VQ03S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2574188166","title":"ImmuneOnco Biopharmaceuticals Seeking HK$351 Million via Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2574188166","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574188166?lang=en_us&edition=fundamental","pubTime":"2025-10-09 10:14","pubTimestamp":1759976054,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said it was looking to raise nearly HK$351 million via a stock offering, according to a Hong Kong bourse filing Thursday.The Chinese developer of tumor therapies is seeking investors for 24.2 million H shares priced at HK$14.50 each to fund the research of its drug pipeline.The shares represent 5.94% of the company's issued share capital and 6.11% of its total issued H shares.UBS is serving as the placing agent for the offering.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2574907776","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Placing Of Total 24.2 MLN New H Shares At HK$14.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2574907776","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574907776?lang=en_us&edition=fundamental","pubTime":"2025-10-09 09:39","pubTimestamp":1759973992,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Placing Of Total 24.2 MLN New H Shares At HK$14.50 Per ShareOct 9  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:PLACING OF TOTAL 24.2 MILLION NEW H SHARES AT HK$14.50 PER SHAREFurther company coverage: 1541.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VP1W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2574890940","title":"ImmuneOnco Biopharmaceuticals Shanghai -  Placing of Total 24.2 Mln New H Shares at HK$14.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2574890940","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574890940?lang=en_us&edition=fundamental","pubTime":"2025-10-09 07:59","pubTimestamp":1759967948,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1191253895","title":"Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 9% Again Following Phase III Clinical Trial Application Submission for IMM2510","url":"https://stock-news.laohu8.com/highlight/detail?id=1191253895","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191253895?lang=en_us&edition=fundamental","pubTime":"2025-10-08 11:14","pubTimestamp":1759893262,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) continued its upward momentum with another surge exceeding 9%. As of press time, the stock was trading 7.94% higher at HK$15.77, with a turnover of HK$21.83 million. On the news...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","HSCEI","01541","BK4614","BK1161","YANG"],"gpt_icon":1},{"id":"1175349071","title":"Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 6% Again as Company Submits Phase III Clinical Trial Application for IMM2510 to CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=1175349071","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175349071?lang=en_us&edition=fundamental","pubTime":"2025-10-03 15:10","pubTimestamp":1759475445,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) continued its upward trajectory, rising over 6% once again. As of press time, the stock gained 6.69% to HK$15.15, with trading volume reaching HK$45.67 million. On the news...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"92c4b57cc171fa2e98d252f2e284036e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","BK4614","CDE","III","BK4017","HSCEI","07226","LU1223082196.USD","LU1223082519.USD","BK4134","YANG","01541","BK1161"],"gpt_icon":1},{"id":"1111436708","title":"Hong Kong Stock Announcements | YUNFENG FIN: Strategic Investment in Global Cryptocurrency Life Insurance Company Anthea and Strategic Cooperation","url":"https://stock-news.laohu8.com/highlight/detail?id=1111436708","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111436708?lang=en_us&edition=fundamental","pubTime":"2025-10-02 23:20","pubTimestamp":1759418429,"startTime":"0","endTime":"0","summary":"**Major Developments** HUTCHMED (00013) will present clinical data at the 2025 European Society for Medical Oncology (ESMO) Annual Congress IMMUNEONCO-B (01541): Submitted Phase III clinical trial...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c0ec3a233b749e19c03b419d858a98d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DEFI","BK1184","08300","BK4588","YANG","BTCO","HSTECH","BK4585","00376","BK4601","BRRR","HSCEI","BK1588","HODL","BITO","01541","BK1501","IBIT","BK1191","BK1156","GBTC","BK1233","BK1587","EZBC","FBTC","BK4614","BK4594","07226","00013","BK1161","BK1584","BK1511","BTCW","00139"],"gpt_icon":1},{"id":"1139563652","title":"IMMUNEONCO-B (01541): Submits Phase III Clinical Trial Application for IMM2510","url":"https://stock-news.laohu8.com/highlight/detail?id=1139563652","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139563652?lang=en_us&edition=fundamental","pubTime":"2025-10-02 08:44","pubTimestamp":1759365855,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that the group has submitted an application to the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK1161","III","01541"],"gpt_icon":0},{"id":"2572009569","title":"ImmuneOnco Biopharmaceuticals (Shanghai) Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2572009569","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572009569?lang=en_us&edition=fundamental","pubTime":"2025-10-02 08:18","pubTimestamp":1759364332,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Submits Phase III Clinical Trial Application for IMM2510 in Immunotherapy-Resistant NSCLC; Regulatory Review Underway in China. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL5Nfxwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","TIL","BK4505","01541","BK4139"],"gpt_icon":0},{"id":"1199621339","title":"IMMUNEONCO-B (01541): IMM0306 Phase III Clinical Trial Application for Treatment of Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1199621339","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199621339?lang=en_us&edition=fundamental","pubTime":"2025-09-29 23:03","pubTimestamp":1759158235,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that the Group has submitted an application for a Phase III clinical trial of IMM0306 to the Center for Drug Evaluation of China's National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","01541","BK4134","BK1161"],"gpt_icon":0},{"id":"2571597330","title":"ImmuneOnco Biopharmaceuticals (Shanghai) Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China(Note: There is no indication of grant/funding or involvement of multiple organizations in the provided announcement; the news is about a regulatory application for a Phase III clinical trial.)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571597330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571597330?lang=en_us&edition=fundamental","pubTime":"2025-09-29 22:59","pubTimestamp":1759157971,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL1VdbbF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2571337768","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc - Submits Phase Iii Trial Application for Imm0306","url":"https://stock-news.laohu8.com/highlight/detail?id=2571337768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571337768?lang=en_us&edition=fundamental","pubTime":"2025-09-29 22:55","pubTimestamp":1759157701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1141949628","title":"Hong Kong Pharmaceuticals Rise as Trump Drug Tariffs Show Limited Impact; Q4 BD Events Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1141949628","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141949628?lang=en_us&edition=fundamental","pubTime":"2025-09-29 14:48","pubTimestamp":1759128513,"startTime":"0","endTime":"0","summary":"Most pharmaceutical stocks gained strength in Hong Kong trading. As of press time, IMMUNEONCO-B (01541) surged 18.98% to HK$13.48; QYUNS-B (02509) climbed 12.11% to HK$32.96; XTALPI (02228) advanced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3452d085f48a0e569f128ec4585d109f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1574","HSCEI","159938","01167","LU2328871848.SGD","07226","BK1161","09939","BK1617","LU1969619763.USD","09995","01541","BK1583","BK4614","BK1515","02509","02228","YANG"],"gpt_icon":0},{"id":"1118629699","title":"Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 12% as IMM2510's Two Phase III Registration Clinical Trials Submit EOP2","url":"https://stock-news.laohu8.com/highlight/detail?id=1118629699","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118629699?lang=en_us&edition=fundamental","pubTime":"2025-09-29 10:40","pubTimestamp":1759113635,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) surged over 12%, and as of press time, it was up 12.27% to HK$12.72, with a trading volume of HK$23.909 million. On the news front, IMMUNEONCO's self-developed VEGF×PD-L1...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3c44d933363e0bc15f0d861a95648d31","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4614","01541","III","YANG","BK1161","07226","HSCEI","BK4134"],"gpt_icon":1},{"id":"1150921357","title":"Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Over 10% on Positive Clinical Trial Progress, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1150921357","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150921357?lang=en_us&edition=fundamental","pubTime":"2025-09-05 13:44","pubTimestamp":1757051056,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) surged over 10% today. As of press time, the stock was up 13.82% to HK$14, with trading turnover reaching HK$82.22 million. On the news front, IMMUNEONCO released its interim...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2562796809","title":"ImmuneOnco Biopharmaceuticals' Loss Narrows in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2562796809","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562796809?lang=en_us&edition=fundamental","pubTime":"2025-08-27 12:22","pubTimestamp":1756268520,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  booked a loss attributable to owners of 152.6 million yuan for the first half of 2025, narrower than a loss of 165.8 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm gained over 2% in Wednesday morning trade.Loss per share came in at 0.37 yuan, compared with 0.44 yuan in the prior-year period.Revenue surged to 38 million yuan from 77,000 yuan.The board declared no dividend.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1197406454","title":"IMMUNEONCO-B (01541) Reports Interim Results with Revenue of RMB 38.027 Million, Surging 49,285.71% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1197406454","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197406454?lang=en_us&edition=fundamental","pubTime":"2025-08-26 21:26","pubTimestamp":1756214794,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 38.027 million, representing a substantial increase of 49,285.71% compared to the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}